Acrivon Therapeutics (ACRV) Cash from Operations (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Cash from Operations of 20538000.0 for Q1 2026, down 5.13% year-over-year from 21649569.93 in Q1 2025, and down 34.79% quarter-over-quarter from 15237000.0 in Q4 2025.
Acrivon Therapeutics (ACRV) Cash from Operations (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Cash from Operations for 6 consecutive years, with 20538000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 5.13% year-over-year to 20538000.0; the TTM figure through Mar 2026 stood at 64668000.0 (up 5.07% YoY), while the FY2025 annual figure was 63665000.0, up 3.05% from the prior year.
- Cash from Operations fell to 20538000.0 in Q1 2026 per ACRV's latest filing, from 15237000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 5824000.0 in Q2 2022 and bottomed at 20538000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 13095882.35 across 5 years, with a median of 12366000.0 in 2023.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 157.9% — and 2025, when it climbed 29.09%.
- Acrivon Therapeutics' Cash from Operations stood at 9354000.0 in 2022, then plunged by 32.2% to 12366000.0 in 2023, then slumped by 40.38% to 17360000.0 in 2024, then climbed by 12.23% to 15237000.0 in 2025, then plunged by 34.79% to 20538000.0 in 2026.
- Business Quant data shows ACRV's Cash from Operations at 20538000.0 in Q1 2026, 15237000.0 in Q4 2025, and 12283000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - | -14.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.86 Mn |
| Jun 30, 2026 | -14.86 Mn |
| Mar 31, 2026 | -20.54 Mn |
| Mar 31, 2026 | -20.54 Mn |
| Dec 31, 2025 | -15.24 Mn |
| Dec 31, 2025 | -15.24 Mn |
| Sep 30, 2025 | -12.28 Mn |
| Sep 30, 2025 | -12.28 Mn |
| Jun 30, 2025 | -16.61 Mn |
| Jun 30, 2025 | -16.61 Mn |
| Mar 31, 2025 | -19.54 Mn |
| Mar 31, 2025 | -19.54 Mn |
| Dec 31, 2024 | -17.36 Mn |
| Dec 31, 2024 | -17.36 Mn |
| Sep 30, 2024 | -17.32 Mn |
| Sep 30, 2024 | -17.32 Mn |
| Jun 30, 2024 | -13.90 Mn |
| Jun 30, 2024 | -13.90 Mn |
| Mar 31, 2024 | -17.08 Mn |
| Mar 31, 2024 | -17.08 Mn |